​

Collegium Pharmaceutical (COLL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

COLL Stock Forecast

Collegium Pharmaceutical (COLL) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $40.25, with a high of $50.00 and a low of $35.00. This represents a 13.67% increase from the last price of $35.41.

$25 $30 $35 $40 $45 $50 High: $50 Avg: $40.25 Low: $35 Last Closed Price: $35.41

COLL Stock Rating

Collegium Pharmaceutical stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 3 Hold (27.27%), 1 Sell (9.09%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 3 7 Strong Sell Sell Hold Buy Strong Buy

COLL Price Target Upside V Benchmarks

TypeNameUpside
StockCollegium Pharmaceutical13.67%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.82%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$38.00
Last Closing Price$35.41$35.41$35.41
Upside/Downside--7.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25221--5
Sep, 25221--5
Aug, 25121--4
Jul, 25121--4
Jun, 25121--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2025David AmsellemPiper Sandler$36.00$30.9316.39%1.67%
Nov 11, 2024Glen SantangeloJefferies$40.00$32.1824.30%12.96%
Sep 04, 2024Oren LivnatH.C. Wainwright$50.00$38.6529.37%41.20%
Aug 09, 2024David AmsellemPiper Sandler$37.00$34.636.84%4.49%
Jul 30, 2024Oren LivnatH.C. Wainwright$47.00$38.6021.76%32.73%
Jun 07, 2024Glen SantangeloJefferies$44.00$31.3640.31%24.26%
May 10, 2024David AmsellemPiper Sandler$39.00$33.1117.79%10.14%
Jan 05, 2023Needham$35.00$26.9829.73%-1.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025Piper SandlerNeutralNeutralhold
Jan 10, 2025NeedhamBuyBuyupgrade
Nov 11, 2024JefferiesBuyBuyhold
Oct 11, 2024Piper SandlerNeutralNeutralhold
Sep 05, 2024SusquehannaNegativedowngrade
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024Piper SandlerNeutralNeutralhold
Jul 30, 2024H.C. WainwrightBuyupgrade
Jun 07, 2024JefferiesUnderperformBuyupgrade
May 10, 2024Sandler O'NeillBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.78$2.05$-0.74$1.60$2.14----
Avg Forecast$3.75$3.84$4.33$5.21$6.18$6.64$7.29$6.87$11.06
High Forecast$3.90$3.99$4.47$5.28$6.27$7.02$8.50$6.94$11.18
Low Forecast$3.65$3.73$4.18$5.11$6.07$6.02$6.08$6.80$10.94
Surprise %-79.20%-46.61%-117.09%-69.29%-65.37%----

Revenue Forecast

$250M $360M $470M $580M $690M $800M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$310.02M$276.87M$463.93M$566.77M$631.45M----
Avg Forecast$311.22M$332.37M$459.50M$564.88M$629.25M$743.38M$754.36M$722.52M$702.30M
High Forecast$320.43M$342.21M$471.01M$565.79M$631.55M$749.26M$762.01M$741.74M$708.08M
Low Forecast$304.54M$325.23M$446.84M$563.21M$626.65M$737.07M$746.71M$703.29M$696.53M
Surprise %-0.39%-16.70%0.96%0.33%0.35%----

Net Income Forecast

$-150M $-20M $110M $240M $370M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.75M$71.52M$-25.00M$48.16M$69.19M----
Avg Forecast$23.54M$54.01M$-81.41M$48.16M$257.86M$272.40M$304.59M$287.15M$462.18M
High Forecast$28.24M$87.25M$-58.87M$61.49M$262.04M$293.29M$355.07M$290.22M$467.12M
Low Forecast$18.83M$20.76M$-103.95M$34.82M$253.68M$251.51M$254.10M$284.08M$457.24M
Surprise %13.66%32.42%-69.29%--73.17%----

COLL Forecast FAQ

Is Collegium Pharmaceutical stock a buy?

Collegium Pharmaceutical stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Collegium Pharmaceutical is a favorable investment for most analysts.

What is Collegium Pharmaceutical's price target?

Collegium Pharmaceutical's price target, set by 11 Wall Street analysts, averages $40.25 over the next 12 months. The price target range spans from $35 at the low end to $50 at the high end, suggesting a potential 13.67% change from the previous closing price of $35.41.

How does Collegium Pharmaceutical stock forecast compare to its benchmarks?

Collegium Pharmaceutical's stock forecast shows a 13.67% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (18.82%).

What is the breakdown of analyst ratings for Collegium Pharmaceutical over the past three months?

  • October 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 25.00% Strong Buy, 50.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Collegium Pharmaceutical’s EPS forecast?

Collegium Pharmaceutical's average annual EPS forecast for its fiscal year ending in December 2025 is $6.64, marking a 210.28% increase from the reported $2.14 in 2024. Estimates for the following years are $7.29 in 2026, $6.87 in 2027, and $11.06 in 2028.

What is Collegium Pharmaceutical’s revenue forecast?

Collegium Pharmaceutical's average annual revenue forecast for its fiscal year ending in December 2025 is $743.38M, reflecting a 17.73% increase from the reported $631.45M in 2024. The forecast for 2026 is $754.36M, followed by $722.52M for 2027, and $702.3M for 2028.

What is Collegium Pharmaceutical’s net income forecast?

Collegium Pharmaceutical's net income forecast for the fiscal year ending in December 2025 stands at $272.4M, representing an 293.70% increase from the reported $69.19M in 2024. Projections indicate $304.59M in 2026, $287.15M in 2027, and $462.18M in 2028.